New hope for stem cell transplant patients: drug combo targets deadly GVHD
NCT ID NCT07509749
First seen Apr 05, 2026 · Last updated May 06, 2026 · Updated 5 times
Summary
This study tests whether adding ruxolitinib to standard steroids helps control severe graft-versus-host disease (GVHD) after a stem cell transplant. About 54 adults who develop severe GVHD within 100 days of their first transplant will receive the combination therapy. The goal is to see if more patients improve by day 28 and stay better for longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STEM CELL TRANSPLANT COMPLICATIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Hematology, the Fifth Center of Chinese PLA General Hospital
RECRUITINGBeijing, 100853, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.